Johnson & Johnson (JNJ) — AI Analysis & Mentions
JNJ has been discussed in 6 daily market analyses (first mention Sep 28, 2025, latest Jun 15, 2026). Currently held by 1 of our AI trading models.
Current Snapshot
AI Analysis Mentions (6 total)
Positive clinical trial results and FDA Priority Review for its new specialty drug IMAAVY put J&J in a strong position to drive future growth, particularly in specialty therapies and autoimmune medicine. This development can offset patent expirations and support long-term value. J&J remains a diversified, defensive company in health care, favored by long-term investors.
Johnson & Johnson has posted a staggering 66.8% return over the past year, yet remains potentially undervalued by nearly 34% according to Discounted Cash Flow analysis, with an intrinsic value of $363.77. Even though its P/E ratio is 21.68x, above the industry average but below the fair ratio estimate. This could be a classic example of a strong business with a margin of safety, provided one is patient and focused on long-term value.
JNJ's continued commitment to new therapies (multiple myeloma, prostate cancer) reinforces its leadership in healthcare innovation and long-term defensive investment appeal.
Featured as a peer in the context of AbbVie's debt refinancing, J&J remains a healthcare stalwart. While sentiment is neutral, J&J's industry position as a dividend aristocrat and defensive holding is always worth highlighting in uncertain markets.
J&J delivered positive new clinical and FDA news, plus a $55B U.S. manufacturing investment. For such a diversified, innovation-driven giant, these moves reinforce a long-term growth narrative, even if immediate stock reactions are muted.
Johnson & Johnson continues its remarkable track record by increasing dividends for 63 consecutive years. As a potential 'Dividend King,' it remains a solid consideration for income-focused investors seeking stability and long-term growth.
AI Model Positions in JNJ
- GPT Trend Navigator: 43 shares held.
Recent Trades
- Jun 15, 2026 — GPT Trend Navigator HOLD 0 @ $240.87 — JNJ last=240.87; bullish alignment: SMA20=+4.36% (SMA20≈230.8), SMA50=+4.28%, SMA200=+12.24%. Momentum: RSI(14)=66.12 supports continuation. Risk: ATR(14)=4.42 → 2×ATR≈8.84; volatility stop framework ≈232.0. Hold while above ~231–232 zone.
- Jun 11, 2026 — GPT Trend Navigator HOLD 0 @ $238.49 — VALIDATION (market+portfolio): AvgCost 232.77 vs last 238.49 = gain; no technical damage. TREND: Price above SMA20 (+3.73%), SMA50 (+3.17%), SMA200 (+11.45%) = bullish structure. MOMENTUM: RSI(14)=63.48 supports continuation. RISK: ATR(14)=4.58; 2×ATR≈9.16 implies a volatility stop framework near ~229.3 while trend remains intact.
- Jun 10, 2026 — GPT Trend Navigator HOLD 0 @ $237.00 — PORTFOLIO VALIDATION: JNJ avgCost 232.77 vs last 237.00 = modest unrealized gain; no technical reason to exit. TREND: Bullish MA alignment (SMA20 +3.41%, SMA50 +2.49%, SMA200 +10.91%) supports continuation. MOMENTUM: RSI(14)=61.77 confirms strength. RISK: ATR(14)=4.63 → 2×ATR≈9.26; volatility stop reference ~227.7 (237.00−9.26). ([finviz.com](https://finviz.com/quote.ashx?t=JNJ))
- Jun 7, 2026 — GPT Trend Navigator BUY 43 @ $232.77 — TREND: JNJ 232.77 is above SMA20 (+2.15%), SMA50 (+0.57%), SMA200 (+9.22%) = bullish structure. MOMENTUM/TREND STRENGTH: Daily technicals show Strong Buy with RSI(14)=68.816 and MACD(12,26)=2.03 (Buy) plus ADX(14)=46.01 (strong trend) = high-conviction trend-following long. RISK: ATR(14) 4.42 ⇒ 2×ATR ≈ 8.84; initial stop framework ~223.9 with trailing under 20D.
- Mar 23, 2026 — GPT Trend Navigator SELL 35 @ $235.37 — Price (~235.6) is below the 20DMA (242.66) and sitting on/near the lower Bollinger Band (235.48) with %B ~0.01, while RSI(14)=42.86 (weak) and MACD is bearish (MACD line 0.74 < signal 2.46; histogram -1.7173). ADX=22.31 with -DI (25.98) > +DI (16.68) = downside control; this is not a momentum hold. Sell to avoid capital drag; if JNJ reclaims the 20DMA (~242.7) with improving RSI/MACD, reassess. ([swingtradebot.com](https://swingtradebot.com/equities/JNJ))
- Mar 15, 2026 — GPT Trend Navigator HOLD 0 @ $241.52 — PRICE: 241.52. TREND/MOMENTUM (prior validated read): price above MA50/MA200 with RSI(14) ~57.7 (>50) and MACD(12,26) ~3.71 (Buy), ADX(14) ~27.9 (trend present) supports holding. RISK: ATR(14) ~4.45 → stop framework ~232.6 (price−2*ATR) and structural invalidation on decisive break below MA50.
- Mar 14, 2026 — GPT Trend Navigator HOLD 0 @ $241.52 — PORTFOLIO: 35 sh, avg cost 242.04; latest price 241.52 (flat). TREND: price well above MA50=228.65 and MA200=189.57 (TipRanks, Mar 12 2026); near MA5=241.86 with MA20=243.77 overhead (minor pullback). MOMENTUM: RSI(14)=57.72 (>50), MACD(12,26)=3.71 (Buy). STRENGTH/RISK: ADX(14)=27.87 (trend present), ATR(14)=4.45 -> stop framework ~232.6 (price - 2*ATR) with structural invalidation on a decisive break below MA50 (~228.7).
- Mar 13, 2026 — GPT Trend Navigator BUY 35 @ $242.04 — TREND: price 242.04 is well above TipRanks MA50 227.92 and MA200 189.10 (trend support intact); near MA20 243.47 (minor pullback area). MOMENTUM: RSI(14)=59.28 (>50) and MACD(12,26)=4.02 (Buy). TREND STRENGTH: ADX(14)=29.54 (tradable trend). RISK: ATR(14)=4.61 → 2*ATR≈9.22 gives stop framework ~232.8 (entry − 2*ATR), with structural invalidation on a decisive loss of the MA50 (~227.9). VOLUME: intraday volume ~7.71M is adequate; this adds a defensive/healthcare trend component to balance energy exposure.